ClinicalTrials.gg
CompletedNCT07661108Updated Nov 12, 2026

A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021)

A Phase 1 interventional study of MK-8527 and Probenecid in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

Updated Nov 12, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Researchers are studying a medicine called MK-8527 to learn how it behaves in the body of healthy adults.

The goal of this study is to learn about the effect of MK-8527 when it is taken with food or with other medicines. Researchers also want to learn about the safety of MK-8527 and if people tolerate it. Tolerate means participants will receive treatment in the trial unless they need to stop it due to health problems.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be in good health
  • Has a (BMI) between 18 and 32 kg/m\^2, inclusive

Exclusion criteria

Exclusion Criteria:

  • Has an estimated (eGFR) ≤90 mL/min/1.73 m\^2
  • Has a history of endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
  • Has a history of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair are allowed)
  • Has a history of cancer ()
  • Is taking any medication that contains emtricitabine (FTC) or lamivudine (3TC)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Part 1: MK-8527

    Participants will receive a single dose of MK-8527 with food and a single dose of MK-8527 without food.

    Drug: MK-8527

  • Experimental
    Part 2: MK-8527 + Probenecid

    Participants will receive a single dose of MK-8527 alone and a single dose of MK-8527 in combination with probenecid.

    Drug: MK-8527 · Drug: Probenecid

  • Experimental
    Part 3: MK-8527 + Itraconazole

    Participants will receive a single dose of MK-8527 alone and a single dose of MK-8527 in combination with itraconazole.

    Drug: MK-8527 · Drug: Itraconazole

Interventions

  • Oral tablet

  • DrugProbenecid

    Oral tablet

  • DrugItraconazole

    Oral solution

06

What researchers measure

Primary outcomes

  1. Part 1: Area Under the Concentration Time Curve From Time 0 to Infinity (AUC0-inf) of MK-8527 in Plasma With and Without Food

    Blood samples will be collected at multiple time points to estimate AUC0-inf of MK-8527 in plasma.

    Time frame: Predose and at designated timepoints (up to 336 hours postdose)

  2. Part 2: AUC0-inf of MK-8527 in Plasma With and Without Probenecid

    Blood samples will be collected at multiple time points to estimate AUC0-inf of MK-8527 in plasma.

    Time frame: Predose and at designated timepoints (up to 336 hours postdose)

  3. Part 3: AUC0-inf of MK-8527 in Plasma With and Without Itraconazole

    Blood samples will be collected at multiple time points to estimate AUC0-inf of MK-8527 in plasma.

    Time frame: Predose and at designated timepoints (up to 336 hours postdose)

Secondary outcomes

  1. Part 1: Area Under the Concentration Time Curve From Time 0 to 336 Hours (AUC0-336) of MK-8527 in Plasma With and Without Food

    Blood samples will be collected at multiple time points to estimate AUC0-336 of MK-8527 in plasma.

    Time frame: Predose and at designated timepoints (up to 336 hours postdose)

  2. Part 1: Time to Maximum Plasma Concentration (Tmax) of MK-8527 in Plasma With and Without Food

    Blood samples will be collected to estimate the Tmax of MK-8527 in plasma.

    Time frame: Predose and at designated timepoints (up to 336 hours postdose)

  3. Part 1: Maximum Plasma Concentration (Cmax) of MK-8527 in Plasma With and Without Food

    Blood samples will be collected to estimate the Cmax of MK-8527 in plasma.

    Time frame: Predose and at designated timepoints (up to 336 hours postdose)

  4. Part 1: Apparent Terminal Half-life (t1/2) of MK-8527 in Plasma With and Without Food

    Blood samples will be collected to estimate the apparent terminal t1/2 of MK-8527 in plasma.

    Time frame: Predose and at designated timepoints (up to 336 hours postdose)

  5. Part 1: Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience AE will be reported.

    Time frame: Up to approximately 43 days

  6. Part 1: Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be reported.

    Time frame: Up to approximately 43 days

  7. Part 2: AUC0-336 of MK-8527 in Plasma With and Without Probenecid

    Blood samples will be collected to estimate the AUC0-336 of MK-8527 in plasma.

    Time frame: Predose and at designated timepoints (up to 336 hours postdose)

  8. Part 2: Tmax of MK-8527 in Plasma with and without Probenecid

    Blood samples will be collected to estimate the Tmax of MK-8527 in plasma.

    Time frame: Predose and at designated timepoints (up to 336 hours postdose)

  9. Part 2: Cmax of MK-8527 in Plasma With and Without Probenecid

    Blood samples will be collected to estimate the Cmax of MK-8527 in plasma.

    Time frame: Predose and at designated timepoints (up to 336 hours postdose)

  10. Part 2: Apparent Terminal t1/2 of MK-8527 in Plasma With and Without Probenecid

    Blood samples will be collected to estimate the apparent terminal t1/2 of MK-8527 in plasma.

    Time frame: Predose and at designated timepoints (up to 336 hours postdose)

  11. Part 2: Urine Concentration at 72 Hours of MK-8527

    Urine samples will be collected to estimate the urine concentration of MK-8527.

    Time frame: At designated timepoints (up to 72 hours postdose)

  12. Part 2: Renal Clearance of MK-8527

    Urine samples will be collected to estimate the renal clearance of MK-8527.

    Time frame: At designated timepoints (up to 72 hours postdose)

  13. Part 2: Number of Participants Who Experience an AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience AE will be reported.

    Time frame: Up to approximately 43 days

  14. Part 2: Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be reported.

    Time frame: Up to approximately 43 days

  15. Part 3: AUC0-336 of MK-8527 in Plasma With and Without Itraconazole

    Blood samples will be collected at multiple time points to estimate AUC0-336 of MK-8527 in plasma.

    Time frame: Predose and at designated timepoints (up to 336 hours postdose)

  16. Part 3: Tmax of MK-8527 in Plasma With and Without Itraconazole

    Blood samples will be collected to estimate the Tmax of MK-8527 in plasma.

    Time frame: Predose and at designated timepoints (up to 336 hours postdose)

  17. Part 3: Cmax of MK-8527 in Plasma With and Without Itraconazole

    Blood samples will be collected to estimate the Cmax of MK-8527 in plasma.

    Time frame: Predose and at designated timepoints (up to 336 hours postdose)

  18. Part 3: Apparent Terminal t1/2 of MK-8527 in Plasma With and Without Itraconazole

    Blood samples will be collected to estimate the apparent t1/2 of MK-8527 in plasma.

    Time frame: Predose and at designated timepoints (up to 336 hours postdose)

  19. Part 3: Urine Concentration at 72 Hours of MK-8527

    Urine samples will be collected to estimate the urine concentration of MK-8527.

    Time frame: At designated timepoints (up to 72 hours postdose)

  20. Part 3: Renal Clearance of MK-8527

    Urine samples will be collected to estimate the renal clearance of MK-8527.

    Time frame: At designated timepoints (up to 72 hours postdose)

  21. Part 3: Number of Participants Who Experience an AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience AE will be reported.

    Time frame: Up to approximately 43 days

  22. Part 3: Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be reported.

    Time frame: Up to approximately 43 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2026 to primary completion in Oct 2026, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2026
First posted
Jun 22, 2026
StartActual
Jun 30, 2026
Primary completionActual
Oct 28, 2026
CompletionActual
Oct 28, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 12, 2026
Primary completion
Oct 9, 2026→Oct 28, 2026 (actual)
Nov 12, 2026
Study completion
Oct 9, 2026→Oct 28, 2026 (actual)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Active, not recruiting→Completed
    Primary completion Oct 9, 2026→Oct 28, 2026 (now actual)
    Study completion Oct 9, 2026→Oct 28, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07661108
Responsible party
Sponsor
First posted
Jun 22, 2026
Start date
Jun 30, 2026
Primary completion
Oct 28, 2026
Completion
Oct 28, 2026
Last update
Nov 12, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alimatravir

Start the discussion